Credit Suisse Ag Alkermes Plc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Alkermes Plc. stock. As of the latest transaction made, Credit Suisse Ag holds 263,943 shares of ALKS stock, worth $7.83 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

263,943

Previous 268,814 1.81%

Holding current value

$7.83 Million

Previous $7.46 Million 4.18%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$26.4 - $32.56 $128,594 - $158,599	-4,871 Reduced 1.81%	263,943 $7.14 Million
Q4 2023 Feb 08, 2024	BUY	$23.37 - $28.68 $1.33 Million - $1.64 Million	57,122 Added 26.98%	268,814 $7.46 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $737,257 - $867,505	-27,135 Reduced 11.36%	211,692 $5.93 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $608,034 - $721,531	21,455 Added 9.87%	238,827 $7.48 Million
Q1 2023 May 10, 2023	BUY	$25.31 - $29.02 $239,230 - $274,297	9,452 Added 4.55%	217,372 $6.13 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $620,572 - $742,198	28,285 Added 15.75%	207,920 $5.43 Million
Q3 2022 Nov 10, 2022	BUY	$22.0 - $31.87 $93,060 - $134,810	4,230 Added 2.41%	179,635 $4.01 Million
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $286,360 - $331,267	-10,847 Reduced 5.82%	175,405 $5.23 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $346,580 - $420,493	15,023 Added 8.77%	186,252 $4.9 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $114,606 - $171,243	5,338 Added 3.22%	171,229 $3.98 Million
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $10.9 Million - $15 Million	-468,255 Reduced 73.84%	165,891 $5.12 Million
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $17.6 Million - $23.5 Million	-935,368 Reduced 59.6%	634,146 $15.5 Million
Q1 2021 May 14, 2021	SELL	$18.21 - $23.2 $884,277 - $1.13 Million	-48,560 Reduced 3.0%	1,569,514 $29.3 Million
Q4 2020 Feb 12, 2021	BUY	$15.39 - $22.1 $20.9 Million - $30.1 Million	1,360,364 Added 527.87%	1,618,074 $32.3 Million
Q3 2020 Nov 13, 2020	SELL	$16.16 - $20.66 $640,485 - $818,838	-39,634 Reduced 13.33%	257,710 $4.27 Million
Q2 2020 Aug 12, 2020	BUY	$13.31 - $19.41 $931,553 - $1.36 Million	69,989 Added 30.78%	297,344 $5.77 Million
Q1 2020 May 13, 2020	SELL	$13.06 - $21.24 $1.95 Million - $3.17 Million	-149,171 Reduced 39.62%	227,355 $3.28 Million
Q4 2019 Feb 12, 2020	BUY	$17.29 - $21.74 $3.36 Million - $4.22 Million	194,148 Added 106.45%	376,526 $7.68 Million
Q3 2019 Nov 12, 2019	SELL	$19.51 - $24.28 $982,835 - $1.22 Million	-50,376 Reduced 21.64%	182,378 $3.56 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $1.26 Million - $2.2 Million	58,888 Added 33.87%	232,754 $5.25 Million
Q1 2019 May 14, 2019	BUY	$28.4 - $36.49 $477,006 - $612,886	16,796 Added 10.69%	173,866 $6.34 Million
Q4 2018 Feb 13, 2019	BUY	$27.94 - $44.61 $61,328 - $97,918	2,195 Added 1.42%	157,070 $4.64 Million
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $1.88 Million - $2.25 Million	-48,723 Reduced 23.93%	154,875 $6.57 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $1.99 Million - $2.52 Million	49,093 Added 31.77%	203,598 $8.38 Million
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $1.93 Million - $2.42 Million	-35,990 Reduced 18.89%	154,505 $8.96 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $6.8 Million - $7.9 Million	-142,605 Reduced 42.81%	190,495 $10.4 Million
Q3 2017 Nov 14, 2017	SELL	$49.16 - $54.45 $1.39 Million - $1.54 Million	-28,251 Reduced 7.82%	333,100 $16.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	361,351	361,351 $20.9 Million

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.87B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account